Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.63 |
| ▸ | CCR1 | P32246 | 1/20 | 0.63 |
| ▸ | CCR5 | P51681 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.63 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114798 | 1.00 | CCR2 (0.63) | CCR2CCR1CCR5CXCR4GNAI3 | |
| SCHEMBL1114624 | 0.90 | CCR2 (0.60) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL1114860 | 0.85 | CCR2 (0.58) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL195514 | 0.85 | CCR2 (0.46) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL1114608 | 0.84 | CCR2 (0.64) | CCR2CCR1CCR5CXCR4GNAI3 | |
| SCHEMBL1114778 | 0.82 | CCR2 (0.62) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL1114664 | 0.82 | CCR2 (0.43) | CCR2CCR1CCR5CXCR4EPHX1 | |
| SCHEMBL2367711 | 0.81 | CCR2 (0.93) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL3688609 | 0.81 | CCR2 (0.93) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL1114672 | 0.80 | CCR2 (0.60) | CCR2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691814-B9 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-02-20 | — | — | EP | claimed |
| EP-1691814-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-07-25 | — | — | EP | claimed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | claimed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | claimed |
| US-20150141460-A1 | Anti-inflammatory Compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8853200-B2 | Treatment of rheumatoid arthritis with 3-amino lactam compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2572716-A1 | Anti-inflammatory Composition | Cambridge Enterprise Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-1691814-B9 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-02-20 | — | — | EP | disclosed |
| EP-1691814-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20120053076-A1 | METHODS FOR IDENTIFICATION | CAMBRIDGE ENTERPRISE LIMITED | 2012-03-01 | — | — | US | disclosed |
| US-7897620-B2 | Methods of using anti-inflammatory compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| EP-2185151-A1 | ANTI-INFLAMMATORY COMPOSITION | Cambridge Enterprise Ltd. (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-7662967-B2 | Anti-inflammatory compounds and compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | CAMBRIDGE ENTERPRISE LIMITED THE OLD SCHOOLS (GB) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016390-A1 | ANTI-INFLAMMATORY COMPOSITION | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | CCR2 1075/4885CCR1 288/4885CCR5 1756/4885 |
| US-20150141460-A1 | Anti-inflammatory Compositions | TNF, PTGES2, IL1B | CCR2 94/4885CCR1 200/4885CCR5 296/4885 |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | TNF, NFKBIA, TPMT | CCR2 207/4885CCR1 214/4885CCR5 706/4885 |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | TNF, PTGES2, MMP8 | CCR2 133/4885CCR1 243/4885CCR5 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.